LianBio's marketing approval for CAMZYOS in Singapore is a positive development for the company. This approval will allow LianBio to market and sell the drug in Singapore, potentially increasing its revenue and expanding its market presence. As a result, this news is likely to have a positive impact on LIAN's stock price in the short term.